WO2005061415A1 - Radical trap in fluoridation of iodonium salt - Google Patents

Radical trap in fluoridation of iodonium salt Download PDF

Info

Publication number
WO2005061415A1
WO2005061415A1 PCT/GB2004/005304 GB2004005304W WO2005061415A1 WO 2005061415 A1 WO2005061415 A1 WO 2005061415A1 GB 2004005304 W GB2004005304 W GB 2004005304W WO 2005061415 A1 WO2005061415 A1 WO 2005061415A1
Authority
WO
WIPO (PCT)
Prior art keywords
reaction
labelled compound
formula
fluoride
anion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2004/005304
Other languages
English (en)
French (fr)
Inventor
Harry John Wadsworth
David Arthur Widdowson
Emmanuelle Wilson
Michael Andrew Carroll
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GE Healthcare Ltd
Original Assignee
GE Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GE Healthcare Ltd filed Critical GE Healthcare Ltd
Priority to US10/559,879 priority Critical patent/US7642373B2/en
Priority to JP2006546303A priority patent/JP4809244B2/ja
Priority to EP04806112A priority patent/EP1697279B1/en
Priority to DE602004016771T priority patent/DE602004016771D1/de
Publication of WO2005061415A1 publication Critical patent/WO2005061415A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se

Definitions

  • the present invention relates to the field of radiochemistry and in particular to radiofluoridation. Specifically, the invention relates to a novel method for the radiofluoridation of iodonium salts wherein a free radical trap is included in the reaction mixture.
  • An additional embodiment of the invention is the radiofluoridation of iodonium salts using a solid phase reaction.
  • Aromatic nucleophilic substitution using the [ 18 F] fluoride anion to displace a suitable leaving group from an electron deficient aromatic ring is known as a method for the production of [ 18 F] fluoroarenes.
  • the nucleophilic substitution reaction is illustrated below:
  • X n represents between 1 and 4 electron withdrawing groups and L represents a suitable leaving group, e.g. fluoro, bromo, nitro, tertiary amino or iodo.
  • the radiochemistry is performed using a nucleophilic radiofluorinating agent such as [ 18 F] caesium fluoride or [ 18 F] potassium fluoride.
  • a phase transfer reagent such as KryptofixTM is used when the radiofluorinating agent is [ 18 F] potassium fluoride.
  • These radiofluorinating agents are prepared from cyclotron-produced no carrier added (NCA) [ 18 F] fluoride [as described by Aigbirhio et al 1995 J Fluorine Chem 70 p279].
  • Decomposition of iodonium salts by a free radical chain reaction process has been identified as a significant factor in the observed yield variability of fluoridation reactions using said iodonium salts. Accordingly, the inclusion of a free radical trap in the reaction mixture blocks the radical chain decomposition pathway for iodonium salts such that only the reaction leading to fluoridation can occur and the yield of aryl fluoride becomes reproducible.
  • the reaction may also be carried out on solid phase. In both the solution and the solid phase the preferred method of the present invention is radiofluoridation.
  • the present invention relates to a method for the production of an aromatic fluorine-labelled compound comprising fluoridation of an iodonium salt with a fluoride ion source characterised in that the reaction mixture contains a free radical trap.
  • the "fluoride ion source" of the present invention is suitably selected from potassium fluoride, caesium fluoride and tetraalkylammonium fluoride.
  • the preferred fluoride ion source of the invention is potassium fluoride which is most preferably activated with a phase transfer reagent, e.g. KryptofixTM.
  • free radical trap is defined as any agent that interacts with free radicals and inactivates them.
  • a suitable free radical trap of the invention is selected from 2,2,6,6- Tetramethylpiperidine-N-Oxide (TEMPO), 1 ,2-diphenylethylene (DPE), ascorbate, para- amino benzoic acid (PABA), ⁇ -tocopherol, hydroquinone, di-t-butyl phenol, ⁇ -carotene and gentisic acid.
  • Preferred free radical traps of the invention are TEMPO and DPE, with TEMPO being most preferred.
  • the reaction mixture usually contains at least 1 Mol% of the radical scavenger and preferably about 2-500 Mol%. A more preferred range is from about 10 to 400 Mol% of radical scavenger in the reaction mixture.
  • iodonium salt is defined in the present invention as a compound comprising an ion of the form Y + .
  • the iodonium salt of the invention is of Formula I:
  • Q is a precursor of the fluorine-labelled compound
  • R 1 -R 5 are independently selected from hydrogen, nitro, cyano, halogen, C _ 10 hydroxyalkyl, C 2 _ ⁇ 0 carboxyalkyl, CMO alkyl. C 2 - 1 0 alkoxyalkyl, C-MO hydroxyalkyl, C-t- 10 aminoalkyl, C- 1 - 1 0 haloalkyl, C 6- ⁇ 4 aryl, C 3 .
  • Y is an anion selected from triflate, nonaflate, mesylate and hexaflate.
  • Alkyl used either alone or as part of another group is defined herein as any straight, branched or cyclic, saturated or unsaturated C n H 2n+ ⁇ group, wherein unless otherwise specified n is an integer between 1 and 6.
  • Aryl used either alone or as part of another group is defined herein as any C ⁇ - molecular fragment or group which is derived from a monocyclic or polycyclic aromatic hydrocarbon, or a monocyclic or polycyclic heteroaromatic hydrocarbon.
  • halogen means a group selected from fluorine, chlorine, bromine, and iodine, including isotopes thereof.
  • Suitable protection for R 1 to R 5 may be achieved using standard methods of protecting group chemistry. After the fluoridation is complete, any protecting groups may be removed by simple procedures which are also standard in the art. Suitable protection and deprotection methodologies may be found, for example, in Protecting Groups in Organic Synthesis, Theodora W. Greene and Peter G. M. Wuts, published by John Wiley & Sons Inc.
  • the iodonium salt of the invention is preferably solid support-bound as in Formula II:
  • Q is a precursor of the fluorine-labelled compound
  • R 1 -R 4 and Y are as defined above for Formula I.
  • the "solid support” may be any suitable solid-phase support which is insoluble in any solvents to be used in the process but to which the linker can be covalently bound.
  • suitable solid support include polymers such as polystyrene (which may be block grafted, for example with polyethylene glycol), polyacrylamide, or polypropylene or glass or silicon coated with such a polymer.
  • the solid support may be in the form of small discrete particles such as beads or pins, or as a coating on the inner surface of a cartridge or on a microfabricated vessel.
  • the "linker” may be any suitable organic group which serves to space the reactive site sufficiently from the solid support structure so as to maximise reactivity.
  • the linker comprises zero to four aryl groups and/or C ⁇ -2 o alkyl, C 2-20 alkoxyalkyl or C ⁇ -20 haloalkyl, and optionally one or more additional substituents such as oxygen, halogen, amide or sulphonamide.
  • the linker may also suitably be a polyethylene glycol (PEG) linker. Examples of such linkers are well known to those skilled in the art of solid-phase chemistry.
  • the precursor Q of Formulae I and II is preferably an aryl group optionally substituted by 1 to 5 substituents independently selected from nitro, cyano, halogen, C 1-10 hydroxyalkyl, C 2 _ ⁇ 0 carboxyalkyl, CMO alkyl, C 2 - ⁇ o alkoxyalkyl, C- O hydroxyalkyl, CMO aminoalkyl, C-MO haloalkyl, C 6 - ⁇ aryl, C 3- ⁇ heteroaryl, C 3-2 o alkylaryl, C5- 12 arylene, C 2 . 10 alkenyl, C2.10 alkynyl, C 1 .
  • acyl C 7-10 aroyl, C 2- ⁇ 0 carboalkoxy, C 2 - ⁇ o carbamoyl, C 2- ⁇ 0 carbamyl, or C-MO alkysulphinyl, or protected versions of any of these groups; or alternatively forms a four- to six-membered ring together with the R group to which it is adjacent, or protected versions thereof.
  • the fluorine-labelled compound of the invention is preferably an [ 18 F]-labelled compound and the fluoride ion source is preferably a source of 18 F .
  • the [ 18 F]- labelled compound is an [ 18 F]-labelled radiotracer, i.e. an [ 18 F]-labelled compound that is suitable for the detection by PET imaging of particular biological targets within a subject.
  • the [ 18 F]-labelled tracer is preferably selected from the compounds listed in the first column of Table I.
  • the respective precursors of these [ 18 F]-labelled tracers are given in the second column of Table I, wherein P 1 -P 4 are each independently hydrogen or a protecting group.
  • R 1a and R 2a are independently selected from hydrogen, a protecting group, Ci 6 alkyl, Ci 6 hydroxyalkyl, and Ci. ⁇ haloalkyl; one of R 3a to R 10a is a bond to the 13 F (in the case of the [ ,8 F]-compound) or one of R 3a to R 10a is a bond to the -l + - group in formula (la) (in the case of the precursor), and the other R groups are independently selected from hydrogen, halo, C ⁇ . ⁇ alkyl, Ci e haloalkyl, Ci s hydroxyalkyl, Ci 6 alkoxy, Ci e haloalkoxy, cyano, and nitro.
  • Most preferred [ 18 F]-labelled compounds of the invention are [ 18 F]-DOPA, [ 8 F]- dopamine, and [ 18 F]-fluorouracil, with [ 18 F]-DOPA
  • the present invention relates to an [ 18 F]-labelled compound produced by the method of the invention.
  • Example 1 describes the attempted fluoridation of diphenyliodonium triflate with potassium fluoride.
  • Example 2 describes the fluoridation method of Example 1 carried out in the presence of 2 mol% TEMPO.
  • Example 3 describes a known method of radiofluoridation of diphenyliodonium triflate which produced highly variable yields.
  • Example 4 describes the method of Example 3 carried out in the presence of 70 mole% TEMPO.
  • the radiochemical yields obtained were considerably more consistent that those obtained in the absence of a radical scavenger suggesting that the variability observed with the method of Example 1 was at least partly as a result of the presence of free radicals.
  • Example 5 describes the method of Example 3 carried out in the presence of 50 mole% 1 ,2-diphenylethylene ( ,2-DPE).
  • the radiochemical yield was similar to that obtained with TEMPO demonstrating that alternative radical traps may also be used.
  • Examples 6-10 describe the radiofluoridation of a variety of other iodonium salts in the presence of varying amounts of TEMPO.
  • a radiochemical yield similar to that obtained in Example 4 for radiofluoridation of diphenyliodonium triflate in the presence of TEMPO was obtained demonstrating that other iodonium salts can be radiofluoridated by the method of the invention.
  • Example 11 describes how the radiofluoridation reaction would be carried out in the case of iodonium salts immobilised onto a solid phase. As has been demonstrated with the solution phase method, it is anticipated that consistent radiochemical yields would also be obtained with this method. Examples 12-15 describe the preparation of various solid-phase bound iodonium salts that may be fluoridated or radiofluoridated by the methods of the invention.
  • reaction mixture was then heated to 80°C for 60 min on an oil bath.
  • the sample was removed from the hot oil, cooled to room temperature by plunging in cold water and the 1 H 13 C and 19 F NMR determined.
  • 1 H, 13 C and 19 F NMR (as appropriate) of fluorobenzene, iodobenzene and benzene in D 3 acetonitrile were also run.
  • the resulting intermediate (assumed to be the fluoride) was converted on heating to iodobenzene and benzene in what must be a reduction reaction. . .
  • Example 5 The method of Example 5 was repeated with the addition to the reaction mixture of TEMPO (3.12mg, 0.002 mmol).
  • Radiochemical purity (RCP) and RCY values obtained are presented in the table below:
  • Example 4 Radiofluoridation of(2-methyl-4-methoxyphenyl)phenyliodonium trifluoroacetate in the presence of 93 mol% TEMPO [ 8 F]-fluoride in 18 O enriched water ( ⁇ 0.4ml) was loaded into the reaction vessel, to this was added a mixture of a solution of Kryptofix (17.9 mg, ex Sigma-Aldrich Chemicals) in acetonitrile (1 ml) and potassium carbonate (0.2 ml of a 0.1 M aqueous solution). The fluoride was dried by azeotropic drying.
  • Example 8 Radiofluoridation of 2-Methoxyphenyl 5'-benzoyloxy-4-methoxy-2- methyl trifluoroacetate in the presence of 100 mol% TEMPO
  • Example 10 Radiofluoridation of (1-methoxypyrazole)(2- methoxyphenyl)iodonium trifluoroacetate in the presence of 50 mol% TEMPO
  • Example 6 The method used was as described above in Example 6 except that (1- methoxypyrazole)(2-methoxyphenyl)iodonium trifluoroacetate was used in place of (2- methyl-4-methoxyphenyl)phenyliodonium trifluoroacetate.
  • Example 11 Radiofluoridation of resin bound iodonium salt in the presence of 50 mol% TEMPO TEMPO (ex Sigma-Aldrich Chemicals) (7.8 mg) in acetonitrile (0.5 ml) is added to the iodonium resin (98.3 mg) and then heated to 100°C and then allowed to cool to ambient temperature.
  • [ 18 F]-fluoride in 8 O enriched water (( ⁇ 0.4ml) is loaded into a separate reaction vessel, to this is added a mixture of a solution of Kryptofix (17.9 mg, ex Sigma- Aldrich Chemicals) in acetonitrile (1ml) and potassium carbonate (0.2 ml of a 0.1 M aqueous solution).
  • the fluoride is dried by azeotropic drying. Following the completion of the drying process, TEMPO (9.6 mg) in dry acetonitrile (1.5 ml) is added and the mixture heated to 80°C for ten minutes, then cooled by a stream of compressed air. The solution is then added to the resin and the reaction heated at 80°C for 10 minutes. The vessel is cooled to 30°C and the product transferred into a product vial. The reaction is analysed by HPLC.
  • 6-(4-iodophenoxy)hexanoic acid - aminomethyl polystyrene resin (1g, 1 mmol) in dichloromethane (15ml) was treated with peracetic acid (5ml). The reaction was stirred with an overhead stirrer forl ⁇ h at room temperature. The reaction was then filtered and the resin washed with dichloromethane (100ml). The resin was then dried in vacuum to give a yellow solid.
  • Example 13 Preparation of6-(2-((S)3-methoxycarbonyl-3-N-t-butoxycarbamyl-4,5- di(t-butoxycarbonyloxy)phen-6-yl)phenoxy)hexanoic acid - amino methyl polystyrene amide trifluoroacetate salt
  • 6-(4-diacetoxyiodophenoxy)hexanoic acid - aminomethyl polystyrene amide in dichloromethane is cooled to -40C is treated with methyl N-£-butoxycarbonyl-3,4-di(f- butoxycarbonyloxy)-6-trimethylstannylphenylalanine. The stirred reaction is then treated with trifluoroacetic acid and allowed to warm to room temperature over 2h. The resin is washed thoroughly with dichloromethane
  • Methyl 11-bromoundecanoate (10g, 35.8mmmol), in acetone (150ml) was treated with 4-iodophenol (7.88g, 35.8mmol) and potassium carbonate (9.88g 71.6mmol).
  • the stirred reaction was heated at reflux for 48h.
  • the reaction was then allowed to cool and the reaction concentrated in vacuo to a gum.
  • the reaction was then partitioned between ethyl acetate (150ml) and water (150ml).
  • the ethyl acetate layer was separated dried, over sodium sulfate and concentrated in vacuo to solid.
  • the solid was dissolved in diethyl ether (100ml) and petroleum ether 60-80C (100ml) added.
  • Methyl 11 -(4-iodophenoxy)undecanoate (1 Og, 23.9mmmol), in methanol (100ml) was treated with sodium hydroxide (2.4g, 60mmol). The stirred reaction was heated at 40C for 60h. The reaction contained a heavy white precipitate at the end of the reaction. The reaction was then cooled to room temperature and concentrated in vacuo. The resulting solid was then treated with 1 N hydrochloric acid (250ml) and ethyl acetate (250ml) and stirred vigorously until the solid had dissolved.
  • 11-(4-iodophenoxy)undecanoic acid - amino polystyrene resin (1g, 1 mmol) in dichloromethane (15ml) was treated with peracetic acid (5ml). The reaction was stirred with an overhead stirrer for 1 ⁇ h at room temperature. The reaction was then filtered and the resin washed with dichloromethane (500ml). The resin was then dried in vacuum to give a yellow solid (990mg).
  • 6-(4-diacetoxyiodophenoxy)undecanoic acid - aminomethyl polystyrene amide in dichloromethane is cooled to -40C is treated with tri-n-butylphenyltin. The stirred reaction is then treated with trifluoroacetic acid and allowed to warm to room temperature over 2h. The resin is washed thoroughly with dichloromethane.
  • Ethyl 6-(4-iodophenoxy)hexanoate (3.62g, 10mmol) was treated with peracetic acid (39%) (5ml) and dichloromethane (15ml) on an ice bath with stirring. The reaction was allowed to warm to room temperature whilst stirred over a period of 2h. The reaction initially darkened but after 30 min became a pale yellow colour. The reaction was then partitioned between dichloromethane (30ml) and water (30ml).
  • Ethyl 6-(4-phenyliodoniumphenoxy)hexanoate (350mg, 0.729mmol) in water/trifluoroacetic acid 1 :1 (10ml) was stirred for 18h at 80C. The reaction was then concentrated in high vacuum to give the products as a gum. The gum was stirred with petroleum ether and the iodonium salt was freed of the solution of the tri-n-butyltin trifluoroacetate from the previous step by decanting off the supernatant solution.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Liquid Crystal (AREA)
  • Saccharide Compounds (AREA)
  • Seasonings (AREA)
PCT/GB2004/005304 2003-12-23 2004-12-17 Radical trap in fluoridation of iodonium salt Ceased WO2005061415A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US10/559,879 US7642373B2 (en) 2003-12-23 2004-12-17 Radical trap in fluoridation of iodonium salt
JP2006546303A JP4809244B2 (ja) 2003-12-23 2004-12-17 ヨードニウム塩のフッ素化におけるラジカル捕捉剤
EP04806112A EP1697279B1 (en) 2003-12-23 2004-12-17 Radical trap in fluoridation of iodinium salt
DE602004016771T DE602004016771D1 (de) 2003-12-23 2004-12-17 Radikalfänger bei der fluorierung von iodiniumsalz

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0329716.5A GB0329716D0 (en) 2003-12-23 2003-12-23 Radical trap
GB0329716.5 2003-12-23

Publications (1)

Publication Number Publication Date
WO2005061415A1 true WO2005061415A1 (en) 2005-07-07

Family

ID=30776291

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2004/005304 Ceased WO2005061415A1 (en) 2003-12-23 2004-12-17 Radical trap in fluoridation of iodonium salt

Country Status (9)

Country Link
US (1) US7642373B2 (https=)
EP (1) EP1697279B1 (https=)
JP (1) JP4809244B2 (https=)
CN (1) CN100415696C (https=)
AT (1) ATE409173T1 (https=)
DE (1) DE602004016771D1 (https=)
ES (1) ES2313117T3 (https=)
GB (1) GB0329716D0 (https=)
WO (1) WO2005061415A1 (https=)

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007073200A1 (en) * 2005-12-21 2007-06-28 Hammersmith Imanet Limited Pet radiotracers
WO2009073273A3 (en) * 2007-10-03 2009-09-17 Ge Healthcare Limited Perfluoro-aryliodonium salts in nucleophilic aromatic 18f-fluorination
WO2010018218A3 (en) * 2008-08-14 2010-04-22 Ge Healthcare Limited Improved fluoridation of iodonium salts
WO2010114723A1 (en) 2009-03-30 2010-10-07 Ge Healthcare Limited Radiolabelling reagents and methods
EP2349977A2 (en) 2008-10-21 2011-08-03 The Board of Regents of the University of Nebraska Fluorination of aromatic ring systems
WO2011141515A1 (en) 2010-05-14 2011-11-17 Bayer Pharma Aktiengesellschaft Diagnostic agents for amyloid beta imaging
US8093405B2 (en) 2008-05-16 2012-01-10 University Of Newcastle Upon Tyne Formation of 18F and 19F fluoroarenes bearing reactive functionalities
US8377704B2 (en) 2009-10-20 2013-02-19 Nutech Ventures Detection and quantification of anions
US8546578B2 (en) 2010-02-04 2013-10-01 Nutech Ventures Iodonium Cyclophanes for SECURE arene functionalization
US20140121371A1 (en) * 2012-10-27 2014-05-01 Ground Fluor Pharmaceuticals, Inc. Processes and reagents for making diaryliodonium salts
EP2417119A4 (en) * 2009-04-08 2014-05-21 Univ California Ý18F¨NUCLEOPHILIC FLUORATION, WITHOUT ADDED COACH, OF AROMATIC COMPOUNDS
WO2014147244A1 (en) 2013-03-22 2014-09-25 Trasis S.A. Stabilization of radiosynthetic intermediates
US9302990B2 (en) 2008-10-21 2016-04-05 Nutech Ventures Fluorination of aromatic ring systems
FR3054445A1 (fr) * 2016-07-26 2018-02-02 Laboratoires Cyclopharma Synthese d'une composition d'agent radioactif
US10071943B2 (en) * 2014-04-11 2018-09-11 The Regents Of The University Of Michigan Copper catalyzed [18F]fluorination of iodonium salts
WO2019185932A1 (en) * 2018-03-29 2019-10-03 Ge Healthcare Limited Stabilised radiolabelling reaction
EP3700512A4 (en) * 2017-10-24 2021-08-11 Lunella Biotech, Inc. MITOFLAVOSCINE: TARGETING FLAVINAL ENZYMES ELIMINATES CANCER STEM CELLS (CSCS) BY INHIBITING MITOCHONDRIAL BREATHING

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0407952D0 (en) * 2004-04-08 2004-05-12 Amersham Plc Fluoridation method
EP2238074A2 (en) * 2008-01-03 2010-10-13 GE Healthcare UK Limited Fluoride processing method
WO2010015340A1 (en) * 2008-08-06 2010-02-11 Bayer Schering Pharma Aktiengesellschaft Daa-pyridine as peripheral benzodiazepine receptor ligand for diagnostic imaging and pharmaceutical treatment
KR101441406B1 (ko) * 2011-05-25 2014-11-04 주식회사 바이오이미징코리아 디아릴이오도늄 염 전구체를 이용한 플로오린-18이 표지된 플루마제닐의 제조 방법
CN105237483B (zh) * 2015-11-10 2018-04-20 东华大学 一种对称型嘧啶基碘鎓盐及其制备方法
US10695450B2 (en) 2016-07-26 2020-06-30 Laboratoires Cyclopharma Synthesis of a radioactive agent composition
JP7556709B2 (ja) * 2019-07-01 2024-09-26 住友化学株式会社 カルボン酸塩、カルボン酸発生剤、レジスト組成物及びレジストパターンの製造方法
JP7627551B2 (ja) * 2019-07-01 2025-02-06 住友化学株式会社 塩、酸発生剤、レジスト組成物及びレジストパターンの製造方法
JP7558694B2 (ja) * 2019-07-01 2024-10-01 住友化学株式会社 塩、酸発生剤、レジスト組成物及びレジストパターンの製造方法
JP2021008455A (ja) * 2019-07-01 2021-01-28 住友化学株式会社 カルボン酸塩、カルボン酸発生剤、レジスト組成物及びレジストパターンの製造方法
GB201915206D0 (en) 2019-10-21 2019-12-04 Ge Healthcare Ltd Use of cyclodextrins as a radiostabilizer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS52133994A (en) * 1976-04-29 1977-11-09 Daikin Ind Ltd Method of fluorination
JP3165775B2 (ja) * 1994-08-31 2001-05-14 日本鋼管株式会社 フッ素放射性同位元素標識l−ドーパの製造方法
JP3171036B2 (ja) * 1994-11-16 2001-05-28 日本鋼管株式会社 フッ素放射性同位元素標識ドーパミンの製造方法
GB0115927D0 (en) * 2001-06-29 2001-08-22 Nycomed Amersham Plc Solid-phase nucleophilic fluorination
GB0206750D0 (en) * 2002-03-22 2002-05-01 Amersham Plc Radiofluorination methods
DE10346228B4 (de) * 2003-09-25 2009-04-09 Eberhard-Karls-Universität Tübingen Universitätsklinikum Herstellung von [18F]fluormarkierten aromatischen L-Aminosäuren
GB0407952D0 (en) * 2004-04-08 2004-05-12 Amersham Plc Fluoridation method

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JACEK J. LUBINKOWSKI ET AL.: "Reactions of Diaryliodononium Salts with Sodium Alkoxides", J. ORG. CHEM., 1975, pages 3010 - 3015, XP002322497 *
SHAH ET AL: "The synthesis of [18-F]fluoroarenes from the reaction of cyclotron-produced [18-F]fluoride ion with diaryliodonium salts]", JOURNAL OF THE CHEMICAL SOCIETY, PERKIN TRANSACTIONS 1, CHEMICAL SOCIETY. LETCHWORTH, GB, vol. 13, 1998, pages 2043 - 2046, XP002313734, ISSN: 0300-922X *
VICTOR W PIKE AND FRANKLIN I. AIGBIRHIO: "Reactions of Cyclotron-produced [18F]Fluoride with Diaryliodonoium Salts - a Novel Single-step Route to N0-carrier-added [18F]Fluoroarenes", J. CHEM. SOC. CHEM. COMMUN., 1995, pages 2215 - 2216, XP002322496 *

Cited By (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8309055B2 (en) 2005-12-21 2012-11-13 Hammersmith Imanet Limited PET radiotracers
WO2007073200A1 (en) * 2005-12-21 2007-06-28 Hammersmith Imanet Limited Pet radiotracers
WO2009073273A3 (en) * 2007-10-03 2009-09-17 Ge Healthcare Limited Perfluoro-aryliodonium salts in nucleophilic aromatic 18f-fluorination
US8093405B2 (en) 2008-05-16 2012-01-10 University Of Newcastle Upon Tyne Formation of 18F and 19F fluoroarenes bearing reactive functionalities
WO2010018218A3 (en) * 2008-08-14 2010-04-22 Ge Healthcare Limited Improved fluoridation of iodonium salts
US8466313B2 (en) 2008-08-14 2013-06-18 Ge Healthcare Limited Fluoridation of iodonium salts
US8604213B2 (en) 2008-10-21 2013-12-10 Nutech Ventures Fluorination of aromatic ring systems
EP2349977A2 (en) 2008-10-21 2011-08-03 The Board of Regents of the University of Nebraska Fluorination of aromatic ring systems
US9302990B2 (en) 2008-10-21 2016-04-05 Nutech Ventures Fluorination of aromatic ring systems
EP2537826A1 (en) 2008-10-21 2012-12-26 Nutech Ventures Fluorination of aromatic ring systems
WO2010114723A1 (en) 2009-03-30 2010-10-07 Ge Healthcare Limited Radiolabelling reagents and methods
EP2417119A4 (en) * 2009-04-08 2014-05-21 Univ California Ý18F¨NUCLEOPHILIC FLUORATION, WITHOUT ADDED COACH, OF AROMATIC COMPOUNDS
US8377704B2 (en) 2009-10-20 2013-02-19 Nutech Ventures Detection and quantification of anions
US8546578B2 (en) 2010-02-04 2013-10-01 Nutech Ventures Iodonium Cyclophanes for SECURE arene functionalization
WO2011141515A1 (en) 2010-05-14 2011-11-17 Bayer Pharma Aktiengesellschaft Diagnostic agents for amyloid beta imaging
US20140121371A1 (en) * 2012-10-27 2014-05-01 Ground Fluor Pharmaceuticals, Inc. Processes and reagents for making diaryliodonium salts
KR102205673B1 (ko) 2013-03-22 2021-01-22 트라시스 에스.에이. 방사성합성 중간체의 안정화
WO2014147244A1 (en) 2013-03-22 2014-09-25 Trasis S.A. Stabilization of radiosynthetic intermediates
BE1021078B1 (fr) * 2013-03-22 2015-04-21 Trasis S.A. Stabilisation d'intermediaires radiosynthetiques
KR20150132829A (ko) * 2013-03-22 2015-11-26 트라시스 에스.에이. 방사성합성 중간체의 안정화
US9796641B2 (en) 2013-03-22 2017-10-24 Trasis S.A. Stabilization of radiosynthetic intermediates
EP2821383A1 (en) * 2013-07-02 2015-01-07 Trasis S.A. Stabilization of radiosynthetic intermediates
US10071943B2 (en) * 2014-04-11 2018-09-11 The Regents Of The University Of Michigan Copper catalyzed [18F]fluorination of iodonium salts
FR3054445A1 (fr) * 2016-07-26 2018-02-02 Laboratoires Cyclopharma Synthese d'une composition d'agent radioactif
EP3700512A4 (en) * 2017-10-24 2021-08-11 Lunella Biotech, Inc. MITOFLAVOSCINE: TARGETING FLAVINAL ENZYMES ELIMINATES CANCER STEM CELLS (CSCS) BY INHIBITING MITOCHONDRIAL BREATHING
US11497749B2 (en) 2017-10-24 2022-11-15 Lunella Biotech, Inc. Mitoflavoscins: targeting flavin-containing enzymes eliminates cancer stem cells (CSCS) by inhibiting mitochondrial respiration
WO2019185932A1 (en) * 2018-03-29 2019-10-03 Ge Healthcare Limited Stabilised radiolabelling reaction
KR20200136451A (ko) * 2018-03-29 2020-12-07 지이 헬쓰케어 리미티드 안정화된 방사성라벨링 반응
US11565257B2 (en) 2018-03-29 2023-01-31 Ge Healthcare Limited Stabilized radiolabelling reaction
KR102786325B1 (ko) 2018-03-29 2025-03-26 지이 헬쓰케어 리미티드 안정화된 방사성라벨링 반응

Also Published As

Publication number Publication date
EP1697279B1 (en) 2008-09-24
DE602004016771D1 (de) 2008-11-06
EP1697279A1 (en) 2006-09-06
JP2007515465A (ja) 2007-06-14
US7642373B2 (en) 2010-01-05
US20060292060A1 (en) 2006-12-28
ES2313117T3 (es) 2009-03-01
GB0329716D0 (en) 2004-01-28
CN100415696C (zh) 2008-09-03
JP4809244B2 (ja) 2011-11-09
ATE409173T1 (de) 2008-10-15
CN1898184A (zh) 2007-01-17

Similar Documents

Publication Publication Date Title
EP1697279B1 (en) Radical trap in fluoridation of iodinium salt
KR100893461B1 (ko) 고상 친핵성 플루오르화 방법
CN1938244B (zh) 氟化方法
EP1572601B1 (en) Solid-phase preparation of 18 f-labelled amino acids
JP4365223B2 (ja) 放射性フッ素化方法
JP2006510705A (ja) ベンゾチアゾール類の固相フッ素化
JP2006510707A (ja) ウラシル及びシトシンの固相フッ素化
CN102119135B (zh) 碘*盐的改进氟化
US7999139B2 (en) Solid-phase preparation of [18F]fluorohaloalkanes
ES2380492T3 (es) Procedimiento para la preparación de HALUROS de [18F]-FLUOROALQUILO
JP2022046502A (ja) アルキル化の方法
WO2011151281A1 (en) Method for production of f-18 labeled amyloid beta ligands
Abudken Synthesis and Fluorination of Diaryliodonium Salts

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200480038469.9

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004806112

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2006546303

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 2006292060

Country of ref document: US

Ref document number: 10559879

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2004806112

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 10559879

Country of ref document: US

WWG Wipo information: grant in national office

Ref document number: 2004806112

Country of ref document: EP